Rachel, W. Miller, MD, Clinical Fellow in the Department of Gynecologic  Oncology, University of Kentucky Healthcare Markey Cancer Center"OVA1 improves the sensitivity of the ACOG referral guidelines for an ovarian mass"Dr. Miller's presentation reported the performance of the current ACOG guidelines and the modified ACOG criteria in the prospective multi-center OVA1 clinical trial.  Replacing CA125 with OVA1 in these guidelines would have improved overall sensitivity for ovarian malignancy from 77% to 94%. This improvement held across both pre- and postmenopausal women and all stages of malignancy. In particular, sensitivity for malignancy among premenopausal women improved from 58% to 91% and from 47% to 88% for premenopausal women with early stage ovarian cancer.

Fred Ueland, M.D., Associate Professor of Gynecologic Oncology at the University of Kentucky's Markey Cancer Center, and principal investigator of the multi-center OVA1 clinical trial, and Dr. Zhen Zhang from the Department of Pathology of Johns Hopkins Medical Institutions"OVA1 Has High Sensitivity in Identifying Ovarian Malignancy Compared to Preoperative Assessment and CA125"Dr. Ueland and Dr. Zhang's presentation evaluated subjects enrolled in the prospective OVA1 clinical trial.  The physician's pre-operative assessment resulted in a sensitivity of 75.2% which would have improved significantly to 95.7% with the addition of OVA1.  Dr. Ueland and Dr. Zhang conclude that "when comb
'/>"/>